Paul McKenzie is retiring effective immediately after a series of setbacks for the biotech, just days before the company was ...

The global biotechnology firm’s shares plunged 12pc when the market opened, with analysts concerned it will not meet full-year guidance.

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit ...

It's been a sad week for CSL Limited ( ASX:CSL ), who've watched their investment drop 16% to AU$152 in the week ...

CSL’s share slump following weak profits and a sudden CEO exit has pulled Australian healthcare stocks to multi-year lows, highlighting sector-wide concerns over regulation and investor sentiment.

A leading investment expert offers his outlook for beaten down CSL shares. The post With FY 2026 profits forecast to grow 4% ...

A leading investment analyst believes CSL shares are trading at a steep discount. The post Why CSL shares could be trading at ...

CSL Limited has announced that Paul McKenzie ceased to be a director of the company on 10 February 2026, with this notice serving as his final director’s interest statement to the ASX. At the time of ...

Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.

COOKE & BIELER LP has opened a new $74.1M position in $CSL, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 report period ...

The latest announcement is out from CSL ( (AU:CSL) ).

Guinness Asset Management LTD has opened a new $10.3M position in $CSL, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 ...